Histopathological and molecular characterization of Egyptian's non melanoma skin cancer
Keywords:
Non melanoma skin cancer, Skin cancer histopathology, RAPD analysis of skin cancer, Skin basal cell carcinoma, Skin squamous cell carcinomaAbstract
In humans, the most prevalent malignant neoplasms are non-melanoma skin cancers (NMSC). Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) account for approximately 95% of all NMSC skin malignancies. In Egypt, sun exposure is responsible for more than 60% of NMSC, while skin color accounts for about 45%. The present study aimed to find sharp and accurate molecular technology to diagnose NMSC beside histopathology. 20 patients of NMSC patients were randomly selected. Tissues skin biopsies were collected from tumor and free areas for histopathological investigation and molecular analysis by random amplified polymorphic DNA (RAPD). Histopathological results revealed that 55.0% of NMSC patients had SCC, 45.0% had BCC. 35.0% of the patients were in early stage and 65.0% were in late stage, but 15.0% were in low grade and 75.0% were in high grade. 90.0% of the cases weren’t metastasized by the tumor while 10.0% were invaded by the tumor. RAPD analysis by OPA-02 primer found a significant (P=0.007) tumor marker band (2000 bp) for SCC patients and no significant bands for BCC. The study succeeded in introducing RAPD for detection of skin cancer beside histopathology.
Downloads
References
1. Hasan N, Nadaf A, Imran M, Jiba U, Sheikh A, Almalki W, et al. Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches. Mol Cancer. 2023; 22(1): 168.
2. Iqbal B, Ali J, Ganguli M, Mishra S, Baboota S. Silymarin-loaded nanostructured lipid carrier gel for the treatment of skin cancer. Nanomedicine. 2019; 14(9): 1077-1093.
3. Zeng L, Gowda B, Ahmed M, Abourehab M, Chen Z, Zhang C, et al. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol Cancer. 2023; 22(1): 10.
4. Jain A, Jain S, Abourehab M, Mehta P, Kesharwani P. An insight on topically applied formulations for management of various skin disorders. J Biomat Sci Polymer Ed. 2022; 33(18): 2406-2432.
5. Dildar M, Akram S, Irfan M, Khan H, Ramzan M, Mahmood A, et al. Skin Cancer Detection: A review using Deep learning techniques. Int J Environ Res Public Health. 2021; 18(10): 5479.
6. Lai V, Cranwell W, Sinclair R. Epidemiology of skin cancer in the mature patient. Clin Dermatol. 2017; 36(2): 167-176.
7. Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, et al. Basal cell carcinoma: A Comprehensive review. Int J Mol Sci. 2020; 21(15): 5572.
8. Corchado-Cobos R, García-Sancha N, González-Sarmiento R, Pérez-Losada J, Cañueto J. Cutaneous squamous cell carcinoma: From biology to therapy. Int J Mol Sci. 2020; 21(8): 2956.
9. Ciążyńska M, Kamińska-Winciorek G, Lange D, Lewandowski B, Reich A, Sławińska M, et al. The incidence and clinical analysis of non-melanoma skin cancer. Scient Rep. 2021; 11(1): 15705.
10. Cañueto J, Cardeñoso E, García JL, Santos-Briz Á, Castellanos-Martín A, Fernández-López E, et al. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. Brit J Dermatol. 2016; 176(5): 1279-1287.
11. Gandhi SA, Kampp J. Skin Cancer Epidemiology, Detection, and Management. Med Clin North Am. 2015; 99(6): 1323-1335.
12. Paolino G, Donati M, Didona D, Mercuri S, Cantisani C. Histology of Non-Melanoma Skin Cancers: An update. Biomedicines. 2017; 5(4): 71.
13. Linares MA, Zakaria A, Nizran P. Skin cancer. Prim Care Clin Office Pract. 2015; 42(4): 645-659.
14. Bouyahya A, Mechchate H, Oumeslakht L, Zeouk I, Aboulaghras S, Balahbib A, et al. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions. Biomolecules. 2022; 12(3): 367.
15. Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Gen. 2016; 48(4): 398-406.
16. Elshikh E, Anan I, Ebaid A, Al Gamal D, Hamed M, Metry A. A Cross-Sectional Epidemiological Cancer Registry in Egypt. Value Health. 2015; 18(7): A437.
17. Khwsky F, Bedwani R, D’Avanzo B, Assaad S, El Shafei A, Mokhtar S, et al. Risk factors for non-melanomatous skin cancer in Alexandria, Egypt. Int J Cancer. 1994; 56(3): 375-378.
18. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: Results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol. 2014; 2014: 1-18.
19. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017; 67(2): 93-99.
20. Tejera-Vaquerizo A, Cañueto J, Llombart B, Martorell-Calatayud A, Sanmartín O. Predictive value of sentinel lymph node biopsy in cutaneous squamous cell carcinoma based on the AJCC-8 and Brigham and Women’s Hospital staging criteria. Dermatol Surg. 2019; 46(7): 857-862.
21. Abdulaziz R, Tawfeek R, Tariq T, Majed S. DNA fingerprinting with the goals of researching the charges made by the parents, studying, and analyzing the data. Medicon Med Sci. 2022; 3(5): 11-17.
22. Babu KN, Sheeja TE, Minoo D, Rajesh MK, Samsudeen K, Suraby EJ, et al. Random amplified polymorphic DNA (RAPD) and derived techniques. Methods Mol Biol. 2021; 2222: 219-247.
23. Sabra SA, Saad AA, Abd El Moneim NA, El Atty Hemida MA, Haroun M. Evaluation of breast cancer regarding molecular and immunochemical markers. Int J Immunother Cancer Res. 2020; 5(1): 001-009.
24. Lu R, Xie S, Wang Y, Zheng H, Zhang H, Deng M, et al. MUS81 participates in the progression of serous ovarian cancer associated with dysfunctional DNA repair system. Front Oncol. 2019; 9: 1189.
25. El-Far M, Abol-Enein H, Zakaria A, El-Gedamy M. Application of random amplified polymorphic DNA-PCR technique in early diagnosis of bladder cancer using urine samples. Curr Topics Biochem Res. 2013; 15(2): 23-33.
26. El-Far M, Abol-Enein H, Zakaria A, El-Gedamy M. Detection of genomic instability in renal cancer by random amplified polymorphic DNA analysis from urine samples as a non-invasive method: potential use in diagnosis. Cancer Sci Res. 2014; 1(1): 1-7.
27. Matta AJ, Pazos AJ, Bustamante-Rengifo JA, Bravo LE. Genomic variability of Helicobacter pylori isolates of gastric regions from two Colombian populations. World J Gastroenterol. 2017; 23(5): 800.
28. Xian ZH. Genetic alterations of hepatocellular carcinoma by random amplified polymorphic DNA analysis and cloning sequencing of tumor differential DNA fragment. World J Gastroenterol. 2005; 11(26): 4102.
29. Nayak R. Histopathology techniques and its management. London, JP Medical Ltd Press, 2017.
30. Ashraf ZM. Molecular characterization of TP53 gene mutations in human bladder cancer. Pharmaceut Biotechnol Curr Res. 2017; 1(2): 1-7.
31. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th edn. USA, John Wiley & Sons Press, 2001.
32. Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.
33. Luo J, Mills K, Cessie SL, Noordam R, Van Heemst D. Ageing, age-related diseases and oxidative stress: What to do next? Ageing Res Rev. 2019; 57: 100982.
34. Schmults CD, Blitzblau R, Aasi SZ, Alam M, Andersen JS, Baumann BC, et al. NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022. J Nat Compreh Cancer Network. 2021; 19(12): 1382-1394.
35. Wetzel M, Strickley J, Haeberle MT, Brown TS. Depth of invasion of aggressive and nonaggressive basal cell carcinoma. J Clin Aesth Dermatol. 2019; 12(3): 12-14.
36. Ribeiro GRH, Francisco G, Teixeira LVS, Romão-Correia RF, Sanches JA Jr, Neto CF, et al. Repetitive DNA alterations in human skin cancers. J Dermatol Sci. 2004; 36(2): 79-86.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
